Arrowhead Pharmaceuticals, Inc.’s share price was $66.25 on January 15th with trailing and forward P/E ratios of 478.56 and 111.11 respectively. The company’s flagship candidate, plozasiran, targets the ApoC3 gene to reduce plasma triglyceride levels, with a PDUFA action date for November 18, 2025. Arrowhead also has other pipeline candidates in development. The company has a solid financial position with $900 million in cash and equivalents, deriving revenue primarily from partnerships. Arrowhead’s market opportunity spans various indications, with upcoming catalysts including trial readouts and milestone payments. Hedge funds are showing interest in Arrowhead, with 40 portfolios holding the stock in the third quarter.

Read more at Yahoo Finance: Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory